Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VICTORION-2 PREVENT inclisiran cardiovascular outcomes trial in established ASCVD
MOH_2022-01-26_010573Phase 3Not yet recruiting
- Sponsor
- Novartis
- Start
- Dec 2021
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, MicroRNA (miRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in atherosclerotic disease comparing Inclisiran with Placebo (2 arms). Primary endpoint: 3-point major adverse cardiovascular events. Planned start Dec 2021; status: not yet recruiting.
02
Drugs
inclisiran
03
Conditions
atherosclerotic disease
Beyond the preview
Go deeper on MOH_2022-01-26_010573.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2022-01-26_010573.